Inhibikase Therapeutics, Inc. Common Stock (IKT)

Price$1.63

Value ScoreD

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-0.69%

Price vs S&P 500 (4W)-20.86%

VGM Score32.31

Market Capitalization$215.21M

All Metrics

Book Value / Share (Quarterly)$1.27

P/TBV (Annual)0.26x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.27

Price vs S&P 500 (YTD)-28.65%

Net Profit Margin (TTM)-5981.25%

EPS (TTM)$-1.15

10-Day Avg Trading Volume0.51M

EPS Excl Extra (TTM)$-1.15

EPS (Annual)$-1.16

ROI (Annual)-29.01%

Net Profit Margin (5Y Avg)-4748.27%

Cash / Share (Quarterly)$1.29

ROA (Last FY)-27.91%

EBITD / Share (TTM)$-0.71

ROE (5Y Avg)-71.16%

Operating Margin (TTM)-6253.12%

Cash Flow / Share (Annual)$-0.21

P/B Ratio1.28x

P/B Ratio (Quarterly)1.32x

Net Income / Employee (Annual)$-786,300

EV / Revenue (TTM)517.62x

Net Interest Coverage (TTM)-738.50x

ROA (TTM)-52.76%

EPS Incl Extra (Annual)$-1.16

Current Ratio (Annual)21.70x

Quick Ratio (Quarterly)29.83x

3-Month Avg Trading Volume1.58M

52-Week Price Return-16.84%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.80

P/S Ratio (Annual)826.15x

Asset Turnover (Annual)0.02x

52-Week High$2.26

Operating Margin (5Y Avg)-4841.72%

EPS Excl Extra (Annual)$-1.16

26-Week Price Return7.24%

Quick Ratio (Annual)21.54x

13-Week Price Return-13.76%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)30.14x

Enterprise Value$165.64M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-25.76%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-7304.75%

Cash / Share (Annual)$1.36

3-Month Return Std Dev59.40%

Net Income / Employee (TTM)$-1,361,600

ROE (Last FY)-29.01%

Net Interest Coverage (Annual)-178.00x

EPS Basic Excl Extra (Annual)$-1.16

P/FCF (TTM)2690.16x

Receivables Turnover (TTM)6.67x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.15

Receivables Turnover (Annual)13.03x

ROI (TTM)-57.15%

P/S Ratio (TTM)672.54x

Pretax Margin (5Y Avg)-4748.27%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.00

Price vs S&P 500 (52W)-41.20%

Year-to-Date Return-20.49%

5-Day Price Return-4.68%

EPS Normalized (Annual)$-1.16

ROA (5Y Avg)-57.11%

Net Profit Margin (Annual)-7304.75%

Month-to-Date Return-6.86%

Cash Flow / Share (TTM)$-3.92

EBITD / Share (Annual)$-1.20

Operating Margin (Annual)-7712.01%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-70.92%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.15

P/TBV (Quarterly)0.36x

P/B Ratio (Annual)1.44x

Pretax Margin (TTM)-5981.25%

Book Value / Share (Annual)$1.31

Price vs S&P 500 (13W)-22.01%

Beta1.02x

P/FCF (Annual)303.12x

Revenue / Share (TTM)$0.00

ROE (TTM)-57.15%

52-Week Low$1.33

vGradeD

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.10est. -0.11

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.18

4.25

4.18

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
IKTInhibikase Therapeutics, Inc. Common Stock	D	—	C	$1.63
AMGNAmgen Inc	C	C	C	$349.58
GILDGilead Sciences Inc	C	B	C	$129.16
ARGXargenx SE American Depositary Shares	D	A	B	$891.32
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$149.23
BIIBBiogen Inc. Common Stock	B	D	B	$195.34
BNTXBioNTech SE American Depositary Share	C	C	D	$88.08
MRNAModerna, Inc. Common Stock	C	B	B	$47.44
NBIXNeurocrine Biosciences Inc	C	B	B	$163.88
EXELExelixis Inc	C	B	B	$52.70
KRYSKrystal Biotech, Inc. Common Stock	D	B	A	$301.00

About

Inhibikase Therapeutics is a clinical-stage biopharmaceutical company developing selective protein kinase inhibitors for neurological disorders. Its lead program, Risvodetinib (IkT-148009), targets Parkinson's disease and related conditions driven by Abelson Tyrosine Kinase dysfunction. The company focuses on disease-modifying therapies for Parkinson's and other neurodegenerative conditions.